Understand the source comparison
Peptide News October 2026: Comparison Table
The October 2026 peptide landscape includes multiple metabolic peptides with overlapping but distinct mechanisms. This comparison synthesizes clinical trial data published or updated in October 2026. Retatrutide 12mg GLP-1 + GIP + glucagon receptor triple agon
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The October 2026 peptide landscape includes multiple metabolic peptides with overlapping but distinct mechanisms. This comparison synthesizes clinical trial data published or updated in October 2026.
- Retatrutide 12mg
- GLP-1 + GIP + glucagon receptor triple agonist
- 24.2% (TRIUMPH-1, Lancet Oct 2026)
- HbA1c −2.39%, liver fat −8.1 percentage points
- 42% nausea, 28% vomiting during titration
- Superior efficacy across weight, glycemic, and hepatic endpoints. New metabolic research benchmark
- Survodutide 4.8mg
- GLP-1 + glucagon dual agonist
- 12.3% (SYNERGY-NASH, Hepatology Oct 2026)
- Liver fat −31.4% relative reduction, 74% achieved ≥30% reduction
- 38% nausea, 24% vomiting
- Hepatic-focused mechanism. Strongest liver fat data of any incretin peptide
- Mazdutide 6mg
- 13.8% (MOMENTUM-3, Diabetes Care Oct 2026)
- HbA1c −2.84% in baseline ≥9.0% cohort, FPG −38%
- 36% nausea, 22% vomiting
- Superior glycemic control in high-baseline HbA1c populations. Glucagon effect on hepatic glucose output
- Tirzepatide 15mg
- GLP-1 + GIP dual agonist
- 20.9% (SURMOUNT-1, baseline comparison)
- HbA1c −2.07%, cardiovascular events −15% (SELECT trial)
- 34% nausea, 20% vomiting
- Established dual-agonist standard. Strong weight and cardiovascular data, lower GI burden than triple agonists
- Semaglutide 2.4mg
- GLP-1 receptor agonist
- 14.9% (STEP-1, baseline comparison)
- HbA1c −1.58%, major adverse cardiovascular events −20% (SELECT trial Aug 2023)
- 44% nausea, 24% vomiting
- Monotherapy benchmark. Extensive safety data, proven cardiovascular benefit, highest nausea rate